{"id":13266,"date":"2025-09-03T18:48:57","date_gmt":"2025-09-03T18:48:57","guid":{"rendered":"https:\/\/latamreports.com\/br\/?p=13266"},"modified":"2025-09-03T18:48:59","modified_gmt":"2025-09-03T18:48:59","slug":"novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia","status":"publish","type":"post","link":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/","title":{"rendered":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia"},"content":{"rendered":"\n<p>A Anvisa aprovou, na \u00faltima segunda-feira, 1\u00ba, o uso do mirvetuximabe soravtansina, conhecido como Elahere. \u00c9 o primeiro tratamento para pacientes com <a href=\"https:\/\/latamreports.com\/br\/pepe-mujica-revela-avanco-de-cancer-e-faz-apelo-por-paz-estou-morrendo\/\">c\u00e2ncer <\/a>de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor de folato alfa (FR\u03b1). A novidade traz esperan\u00e7a para mulheres com poucas op\u00e7\u00f5es de tratamento.<\/p>\n\n\n\n<p>O Elahere \u00e9 um conjugado anticorpo-f\u00e1rmaco (ADC). Ele combina um anticorpo direcionado ao receptor FR\u03b1 com uma carga quimioter\u00e1pica capaz de destruir as c\u00e9lulas tumorais, poupando a maior parte das c\u00e9lulas saud\u00e1veis. \u201cResistente \u00e0 platina\u201d significa que o c\u00e2ncer retorna em at\u00e9 seis meses ap\u00f3s o t\u00e9rmino da quimioterapia convencional. J\u00e1 \u201cFR\u03b1 positivo\u201d indica que as c\u00e9lulas tumorais possuem o receptor que o medicamento utiliza como alvo. Cerca de um ter\u00e7o das pacientes apresenta essa caracter\u00edstica.<\/p>\n\n\n\n<p>Segundo estudo publicado no <em>New England Journal of Medicine<\/em> pela AbbVie, \u00e9 a primeira terapia que demonstra benef\u00edcio em sobrevida global para esse grupo de pacientes em ensaios cl\u00ednicos de fase 3.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Resultados promissores em estudo cl\u00ednico<\/h2>\n\n\n\n<p>O estudo envolveu mais de 450 pacientes. O novo tratamento reduziu em 35% o risco de progress\u00e3o da <a href=\"https:\/\/latamreports.com\/br\/botafogo-surpreende-ao-revelar-mancha-no-uniforme-em-campanha-contra-cancer-de-pele\/\">doen\u00e7a<\/a>, quando comparado \u00e0 quimioterapia convencional. A sobrevida global m\u00e9dia foi de 16,5 meses para quem recebeu Elahere, contra 12,7 meses no grupo de quimioterapia tradicional. A taxa de resposta objetiva, que mede a redu\u00e7\u00e3o do tumor, foi de 42%, contra 16% na compara\u00e7\u00e3o. Os resultados foram apresentados no congresso da ASCO (Sociedade Americana de Oncologia Cl\u00ednica).<\/p>\n\n\n\n<p>O uso do medicamento depende de teste de imuno-histoqu\u00edmica. Ele identifica pacientes com alta express\u00e3o do receptor FR\u03b1 e j\u00e1 est\u00e1 dispon\u00edvel em laborat\u00f3rios brasileiros. \u201c\u00c9 fundamental testar o status do FR\u03b1 para definir quem pode se beneficiar do tratamento\u201d, explica a oncologista americana Kathleen Moore, coordenadora de parte do estudo.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Avan\u00e7o no Brasil e impacto para pacientes<\/h3>\n\n\n\n<p>O c\u00e2ncer de ov\u00e1rio \u00e9 uma das principais causas de morte por c\u00e2ncer ginecol\u00f3gico. No Brasil, o INCA estima cerca de 7,3 mil novos casos por ano. A doen\u00e7a \u00e9 geralmente diagnosticada em est\u00e1gio avan\u00e7ado e tende a reaparecer ap\u00f3s o tratamento inicial.<\/p>\n\n\n\n<p>Com a aprova\u00e7\u00e3o do Elahere, o pa\u00eds passa a contar com uma nova op\u00e7\u00e3o terap\u00eautica. Ainda n\u00e3o h\u00e1 defini\u00e7\u00e3o sobre inclus\u00e3o no rol da ANS ou no SUS. Nos Estados Unidos e na Europa, o medicamento j\u00e1 havia sido autorizado em 2024. No Brasil, a chegada do f\u00e1rmaco \u00e9 um marco. H\u00e1 mais de oito anos n\u00e3o surgia alternativa para pacientes resistentes \u00e0 platina.<\/p>\n\n\n\n<p>Para a oncologista Graziela Dal Molin, vice-presidente do Grupo Brasileiro de Tumores Ginecol\u00f3gicos (EVA) e diretora do IGCS, o medicamento representa avan\u00e7o in\u00e9dito.<\/p>\n\n\n\n<p>\u201cO mirvetuximabe \u00e9 parte da classe dos ADCs, uma quimioterapia mais eficaz por atuar em receptores espec\u00edficos do c\u00e2ncer. Isso garante efici\u00eancia maior com menos efeitos colaterais. Pela primeira vez em mais de 20 anos, vimos desfecho positivo em sobrevida global nesse cen\u00e1rio.\u201d<\/p>\n\n\n\n<p>Apesar de n\u00e3o ser curativo, o f\u00e1rmaco reduz tumores, alivia sintomas, melhora a qualidade de vida e aumenta a sobrevida. \u00c9 especialmente relevante para pacientes com tumores avan\u00e7ados e poucas op\u00e7\u00f5es. Graziela refor\u00e7a que o medicamento n\u00e3o \u00e9 indicado para todas. Apenas pacientes com tumor FR\u03b1 positivo se beneficiam. Quando positivo, o tratamento \u00e9 eficaz em cerca de 40% dos casos.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Anvisa aprovou, na \u00faltima segunda-feira, 1\u00ba, o uso do mirvetuximabe soravtansina, conhecido como Elahere. \u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio &#8230; <a title=\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia\" class=\"read-more\" href=\"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/\" aria-label=\"Read more about Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":13267,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2],"tags":[31],"class_list":["post-13266","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-negocios","tag-brasil","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio<\/title>\n<meta name=\"description\" content=\"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio\" \/>\n<meta property=\"og:description\" content=\"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/\" \/>\n<meta property=\"og:site_name\" content=\"LatAm Reports\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/latamreports\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T18:48:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T18:48:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LatAm Reports Redatores da Equipe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@latamreports\" \/>\n<meta name=\"twitter:site\" content=\"@latamreports\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LatAm Reports Redatores da Equipe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/\"},\"author\":{\"name\":\"LatAm Reports Redatores da Equipe\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\"},\"headline\":\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia\",\"datePublished\":\"2025-09-03T18:48:57+00:00\",\"dateModified\":\"2025-09-03T18:48:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/\"},\"wordCount\":576,\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/medicamento-cancer-de-ovario.png\",\"keywords\":[\"Brasil\"],\"articleSection\":[\"Neg\u00f3cios\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/\",\"name\":\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/medicamento-cancer-de-ovario.png\",\"datePublished\":\"2025-09-03T18:48:57+00:00\",\"dateModified\":\"2025-09-03T18:48:59+00:00\",\"description\":\"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/medicamento-cancer-de-ovario.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/medicamento-cancer-de-ovario.png\",\"width\":1200,\"height\":630,\"caption\":\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"name\":\"LatAm Reports\",\"description\":\"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas\",\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/latamreports.com\\\/br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\",\"name\":\"LatAm Reports\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"width\":2522,\"height\":1014,\"caption\":\"LatAm Reports\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/latamreports\",\"https:\\\/\\\/x.com\\\/latamreports\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\",\"name\":\"LatAm Reports Redatores da Equipe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"caption\":\"LatAm Reports Redatores da Equipe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio","description":"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/","og_locale":"en_US","og_type":"article","og_title":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio","og_description":"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...","og_url":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/","og_site_name":"LatAm Reports","article_publisher":"https:\/\/facebook.com\/latamreports","article_published_time":"2025-09-03T18:48:57+00:00","article_modified_time":"2025-09-03T18:48:59+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png","type":"image\/png"}],"author":"LatAm Reports Redatores da Equipe","twitter_card":"summary_large_image","twitter_creator":"@latamreports","twitter_site":"@latamreports","twitter_misc":{"Written by":"LatAm Reports Redatores da Equipe","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#article","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/"},"author":{"name":"LatAm Reports Redatores da Equipe","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70"},"headline":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia","datePublished":"2025-09-03T18:48:57+00:00","dateModified":"2025-09-03T18:48:59+00:00","mainEntityOfPage":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/"},"wordCount":576,"publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"image":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png","keywords":["Brasil"],"articleSection":["Neg\u00f3cios"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/","url":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/","name":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#primaryimage"},"image":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png","datePublished":"2025-09-03T18:48:57+00:00","dateModified":"2025-09-03T18:48:59+00:00","description":"\u00c9 o primeiro tratamento para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina e que apresentam o receptor...","breadcrumb":{"@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#primaryimage","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/medicamento-cancer-de-ovario.png","width":1200,"height":630,"caption":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia"},{"@type":"BreadcrumbList","@id":"https:\/\/latamreports.com\/br\/novo-medicamento-oferece-esperanca-para-cancer-de-ovario-resistente-a-quimioterapia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/latamreports.com\/br\/"},{"@type":"ListItem","position":2,"name":"Novo medicamento oferece esperan\u00e7a para c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia"}]},{"@type":"WebSite","@id":"https:\/\/latamreports.com\/br\/#website","url":"https:\/\/latamreports.com\/br\/","name":"LatAm Reports","description":"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas","publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/latamreports.com\/br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/latamreports.com\/br\/#organization","name":"LatAm Reports","url":"https:\/\/latamreports.com\/br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","width":2522,"height":1014,"caption":"LatAm Reports"},"image":{"@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/latamreports","https:\/\/x.com\/latamreports"]},{"@type":"Person","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70","name":"LatAm Reports Redatores da Equipe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","caption":"LatAm Reports Redatores da Equipe"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/13266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/comments?post=13266"}],"version-history":[{"count":2,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/13266\/revisions"}],"predecessor-version":[{"id":13269,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/13266\/revisions\/13269"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media\/13267"}],"wp:attachment":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media?parent=13266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/categories?post=13266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/tags?post=13266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}